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ABSTRACT 
The larger context of clinical trials in India is poverty and the absence of affordable healthcare. For more than a decade, government policy has been 
to reduce public support for healthcare services, and these services are under-resourced. Health economists have pointed out that only 15 per cent 
of the Rs 1,500 billion spent in the health sector in India comes from the government. Clinical trials (also called medical research studies) are used 
to determine whether new drugs or treatments are both safe and effective. Carefully conducted clinical trials are the fastest and safest way to find 
treatments that work in people. If the drug successfully passes through Phases I, II, and III, it will usually be approved by the national regulatory 
authority for use in the general population. Phase IV are 'post-approval' studies. The level of concern about the impact of the CTD on clinical 
research activities is intense and widespread overall stakeholder groups. Opinions and quantitative survey results draw a picture of increased 
bureaucracy and costs, reduction of important research without creating benefits for patients. However, concrete, comprehensive figures about the 
clinical trial activities are only available from competent authorities. Figures on the CTD’s impact on organisation, staffing, costs and processes of 
the different stakeholders are missing.These trials violated the the Indian Council of Medical Research’s Ethical guidelines for biomedical research 
on human subjects and the World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. The 
trial designs do not seem to have violated regulations for the conduct of clinical research in India. The existing regulatory apparatus therefore 
permits unethical trials of no benefit to Indians. Clearly, trials are being conducted in India that could not be conducted in developed countries, 
taking advantage of people’s lack of access to affordable, good quality care.  
The benefits of research do not reach the community as drugs found effective following these trials may not be affordable to the community in 
which they were tested. Such practices are in violation of the Declaration of Helsinki as well as the general principles laid down in the Indian Council 
of Medical Research’s ethical guidelines for biomedical research.The infrastructure for regulation, ethics review and monitoring is insufficient. The 
government’s priority seems to be ensuring that clinical research in India produces good quality data according to Good Clinical Practice standards. 
Ethical guidelines – including its own ethical guidelines – seem to be of secondary importance. The ethical concerns raised by these clinical trials; 
the weak regulatory apparatus to protect trial participants, government policy to encourage international clinical trials without taking active steps 
to put in place a system to protect participants from harm; people’s desperation for affordable health care – all this will only worsen the harm being 
done to trial participants in India.tum since the dis 
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INTRODUCTION 
A clinical trial is a research study in human subjects with the aim of 
answering specific questions about a new medical treatment 
(vaccines, new therapies or new ways of using known treatments). 
Clinical trials (also called medical research and research studies) are 
used to determine whether new drugs or treatments are both safe 
and effective. Pharmaceutical clinical trials are conducted in Phases. 
The trials at each Phase have a different purpose and each Phase 
looks at different areas (e.g. toxicity, dose finding etc) Clinical trials 
often involve patients with specific health conditions who then 
benefit from receiving otherwise unavailable treatments. In early 
phases, participants are healthy volunteers who receive financial 
incentives for their inconvenience. During dosing periods, study 
subjects typically remain on site at the unit for durations of anything 
from 1 to 30 nights, occasionally longer, although is not always 
required In planning a clinical trial, the sponsor or investigator first 
identifies the medication or device to be tested. Usually, one or more 
pilot experiments are conducted to gain insights for design of the 
clinical trial to follow.  
In medical jargon, effectiveness is how well a treatment works in 
practice and efficacy is how well it works in a clinical trial. In the 
U.S., the elderly comprise only 14% of the population but they 
consume over one-third of drugs (Avorn, 2004). Despite this, they 
are often excluded from trials because their more frequent health 
issues and drug use produces unreliable data. Women, children, and 
people with unrelated medical conditions are also frequently 
excluded (Van at el., 2007). In coordination with a panel of expert 
investigators  (usually physicians  well known for their  publications  
 
and clinical experience), the sponsor decides what to compare the 
new agent with (one or more existing treatments or a placebo), and 
what kind of patients might benefit from the medication or device. If 
the sponsor cannot obtain enough patients with this specific disease 
or condition at one location, then investigators at other locations 
who can obtain the same kind of patients to receive the treatment 
would be recruited into the study. During the clinical trial, the 
investigators: recruit patients with the predetermined 
characteristics, administer the treatment(s), and collect data on the 
patients' health for a defined time period. These patients are 
voluntaries and they are not paid for participating in clinical trials. 
These data include measurements like vital signs, concentration of 
the study drug in the blood, and whether the patient's health 
improves or not. The researchers send the data to the trial sponsor 
who then analyzes the pooled data using statistical tests. 
Some examples of what a clinical trial may be designed to do 
• Assess the safety and effectiveness of a new medication or device 
on a specific kind of patient (e.g., patients who have been diagnosed 
with Alzheimer's disease) 
• Assess the safety and effectiveness of a different dose of a 
medication than is commonly used (e.g., 10 mg dose instead of 5 mg 
dose) 
• Assess the safety and effectiveness of an already marketed 
medication or device for a new indication, i.e. a disease for which the 
drug is not specifically approved 
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•   Assess whether the new medication or device is more effective for 
the patient's condition than the already used, standard medication 
or device ("the gold standard" or "standard therapy") 
•  Compare the effectiveness in patients with a specific disease of 
two or more already approved or common interventions for that 
disease (e.g., Device A vs. Device B, Therapy A vs. Therapy B) 
Note that while most clinical trials compare two medications or 
devices, some trials compare three or four medications, doses of 
medications, or devices against each other. Except for very small 
trials limited to a single location, the clinical trial design and 
objectives are written into a document called a clinical trial protocol. 
The protocol is the 'operating manual' for the clinical trial, and 
ensures that researchers in different locations all perform the trial in 
the same way on patients with the same characteristics. (This 
uniformity is designed to allow the data to be pooled.) A protocol is 
always used in multicenter trials. Because the clinical trial is 
designed to test hypotheses and rigorously monitor and assess what 
happens, clinical trials can be seen as the application of the scientific 
method to understanding human or animal biology. 
The most commonly performed clinical trials evaluate new drugs, 
medical devices (like a new catheter), biologics, psychological 
therapies, or other interventions. Clinical trials may be required 
before the national regulatory authority approves marketing of the 
drug or device, or a new dose of the drug, for use on patients. 
Beginning in the 1980s, harmonization of clinical trial protocols was 
shown as feasible across countries of the European Union.  
At the same time, coordination between Europe, Japan and the 
United States led to a joint regulatory-industry initiative on 
international harmonization named after 1990 as the International 
Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) Currently, 
most clinical trial programs follow ICH guidelines, aimed at 
"ensuring that good quality, safe and effective medicines are 
developed and registered in the most efficient and cost-effective 
manner.  
These activities are pursued in the interest of the consumer and 
public health, to prevent unnecessary duplication of clinical trials in 
humans and to minimize the use of animal testing without 
compromising the regulatory obligations of safety and 
effectiveness." Trial is from the Anglo–French Trier, meaning to try. 
Broadly, it refers to the action or process of putting something to a 
test or proof.  
Clinical is from clinic, from the French cliniqu´e and from the Greek 
klinike, and refers to the practice of caring for the sick at the be 
dside. Hence, narrowly, a clinical trial is the action or process of 
putting something to a test or proof at the bedside of the sick. 
However, broadly it refers to any testing done on human beings for 
the sake of determining the value of a treatment for the sick or for 
preventing disease or sickness. 
The concepts behind clinical trials, however, are ancient. The Book 
of Daniel verses 12 through 15, for instance, describes a planned 
experiment with both baseline and follow-up observations of two 
groups who either partook of, or did not partake of, "the King's 
meat" over a trial period of ten days. 
 Persian physician and philosopher, Avicenna, gave such inquiries a 
more formal structure.[9] In The Canon of Medicine in 1025 AD, he 
laid down rules for the experimental use and testing of drugs and 
wrote a precise guide for practical experimentation in the process of 
discovering and proving the effectiveness of medical drugs and 
substances.[10] He laid out the following rules and principles for 
testing the effectiveness of new drugs and medications: [11][12] 
 The drug must be free from any extraneous accidental quality. 
 It must be used on a simple, not a composite, disease. 
 The drug must be tested with two contrary types of diseases, 
because sometimes a drug cures one disease by its essential 
qualities and another by its accidental ones. 
 The quality of the drug must correspond to the strength of the 
disease. For example, there are some drugs whose heat is less 
than the coldness of certain diseases, so that they would have 
no effect on them. 
 The time of action must be observed, so that essence and 
accident are not confused. 
 The effect of the drug must be seen to occur constantly or in 
many cases, for if this did not happen, it was an accidental 
effect. 
 The experimentation must be done with the human body, for 
testing a drug on a lion or a horse might not prove anything 
about its effect on man. 
One of the most famous clinical trials was James Lind's 
demonstration in 1747 that citrus fruits cure scurvy.[13]  
He compared the effects of various different acidic substances, 
ranging from vinegar to cider, on groups of afflicted sailors, and 
found that the group who were given oranges and lemons had 
largely recovered from scurvy after 6 days. 
Frederick Akbar Mahomed (d. 1884), who worked at Guy's Hospital 
in London,[14] made substantial contributions to the process of 
clinical trials during his detailed clinical studies, where "he 
separated chronic nephritis with secondary hypertension from what 
we now term essential hypertension."  He also founded "the 
Collective Investigation Record for the British Medical Association; 
this organization collected data from physicians practicing outside 
the hospital setting and was the precursor of modern collaborative 
clinical trials."[15] 
TYPE OF CLINICAL TRIAL 
There are several types of clinical trials: 
Prevention trials 
Look for better ways to prevent disease in people who have never 
had the disease or to prevent a disease from returning. These 
approaches may include medicines, vitamins, vaccines, minerals, or 
lifestyle changes. Prevention trials test new approaches, such as 
medications,vitamins, or other supplements, that doctors believe 
may lower the risk of developing a certain type of cancer. Most 
prevention trials are conducted with healthy people who have not 
had cancer. Some trials are conducted with people who have had 
cancer and want to prevent recurrence (return of cancer), or reduce 
the chance of developing a new type of cancer. 
Screening trials 
test the best way to detect certain diseases or health conditions. 
Screening trials study ways to detect cancer earlier. They are often 
conducted to determine whether finding cancer before it causes 
symptoms decreases the chance of dying from the disease. These 
trials involve people who do not have any symptoms of cancer. 
Diagnostic trials  
conducted to find better tests or procedures for diagnosing a 
particular disease or condition. Diagnostic trialsstudy tests or 
procedures that could be used to identify cancer more accurately. 
Diagnostic trials usually include people who have signs or symptoms 
of cancer.  
Treatment trials 
 Test experimental treatments, new combinations of drugs, or new 
approaches to surgery or radiation therapy. Treatment trials are 
conducted with people who have cancer. They are designed to 
answer specific questions about, and evaluate the effectiveness of, a 
new treatment or a new way of using astandard treatment. These 
trials test many types of treatments, such as new drugs, vaccines, 
new approaches to surgery orradiation therapy, or new 
combinations of treatments. 
Quality of life trials  
explore ways to improve comfort and the quality of life for 
individuals with a chronic illness (a.k.a. Supportive Care trials). 
Quality-of-life (also called supportive care) trials explore ways to 
improve the comfort and quality of life of cancer patients and cancer 
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survivors. These trials may study ways to help people who are 
experiencing nausea, vomiting, sleep disorders,depression, or other 
effects from cancer or its treatment. 
Compassionate use trials or expanded access  
provide partially tested, unapproved therapeutics prior to a small 
number of patients that have no other realistic options. Usually, this 
involves a disease for which no effective therapy exists, or a patient 
that has already attempted and failed all other standard treatments 
and whose health is so poor that he does not qualify for participation 
in randomized clinical trials. Usually, case by case approval must be 
granted by both the FDA and the pharmaceutical company for such 
exceptions. 
Genetics studies are sometimes part of another cancer clinical trial. 
The genetics component of the trial may focus on how 
geneticmakeup can affect detection, diagnosis, or response to cancer 
treatment. 
DESIGN OF CLINICAL STUDY 
A fundamental distinction in evidence-based medicine is between 
observational studies and randomized controlled trials. Types of 
observational studies in epidemiology such as the cohort study and 
the case-control study provide less compelling evidence than the 
randomized controlled trial. In observational studies, the 
investigators only observe associations (correlations) between the 
treatments experienced by participants and their health status or 
diseases. 
A randomized controlled trial is the study design that can provide 
the most compelling evidence that the study treatment causes the 
expected effect on human health. Currently, some Phase II and most 
Phase III drug trials are designed as randomized, double blind, and 
placebo-controlled. 
Randomized 
Each study subject is randomly assigned to receive either the study 
treatment or a placebo. 
Blind 
The subjects involved in the study do not know which study 
treatment they receive. If the study is double-blind, the researchers 
also do not know which treatment is being given to any given 
subject.  This 'blinding' is to prevent biases, since if a physician knew 
which patient was getting the study treatment and which patient 
was getting the placebo, he/she might be tempted to give the 
(presumably helpful) study drug to a patient who could more easily 
benefit from it.  
In addition, a physician might give extra care to only the patients 
who receive the placebos to compensate for their ineffectiveness. A 
form of double-blind study called a "double-dummy" design allows 
additional insurance against bias or placebo effect.   
In this kind of study, all patients are given both placebo and active 
doses in alternating  periods of time during the study. 
Placebo-controlled 
The use of a placebo (fake treatment) allows the researchers to 
isolate the effect of the study treatment.  
Although the term "clinical trials" is most commonly associated with 
the large, randomized studies typical of Phase III, many clinical trials 
are small.  
They may be "sponsored" by single physicians or a small group of 
physicians, and are designed to test simple questions. In the field of 
rare diseases sometimes the number of patients might be the 
limiting factor for a clinical trial.  
Other clinical trials require large numbers of participants (who may 
be followed over long periods of time), and the trial sponsor is a 
private company, a government health agency, or an academic 




An essential component of initiating a clinical trial is to recruit study 
subjects following procedures using a signed document called 
"informed consent".[19] 
Informed consent is a legally-defined process of a person being told 
about key facts involved in a clinical trial before deciding whether or 
not to participate.  
To fully describe participation to a candidate subject, the doctors 
and nurses involved in the trial explain the details of the study using 
terms the person will understand. Foreign language translation is 
provided if the participant's native language is not the same as the 
study protocol. 
The research team provides an informed consent document that 
includes trial details, such as its purpose, duration, required 
procedures, risks, potential benefits and key contacts.  
The participant then decides whether or not to sign the document in 
agreement. Informed consent is not an immutable contract, as the 
participant can withdraw at any time without penalty. 
Statistical power 
In designing a clinical trial, a sponsor must decide on the target 
number of patients who will participate. The sponsor's goal usually 
is to obtain a statistically significant result showing a significant 
difference in outcome (e.g., improvement percentage in the 
treatment of psoriasis using hydrocortisone after 42 days).[20] 
Between the groups of patients who receive the study treatment and 
those who receive a placebo or a different treatment.  
The number of patients required to give a statistically significant 
result depends on the question the trial wants to answer. For 
example, to show the effectiveness of a new drug in a non-curable 
disease as metastatic kidney cancer requires many fewer patients 
than in a highly curable disease as seminoma if the drug is compared 
to a placebo. 
The number of patients enrolled in a study has a large bearing on the 
ability of the study to reliably detect the size of the effect of the study 
intervention. This is described as the "power" of the trial.  
The larger the sample size or number of participants in the trial, the 
greater the statistical power. 
However, in designing a clinical trial, this consideration must be 
balanced with the fact that more patients make for a more expensive 
trial.  
The power of a trial is not a single, unique value; it estimates the 
ability of a trial to detect a difference of a particular size (or larger) 
between the treated (tested drug/device) and control (placebo or 
standard treatment) groups.  
By example, a trial of a lipid-lowering drug versus placebo with 100 
patients in each group might have a power of .90 to detect a 
difference between patients receiving study drug and patients 
receiving placebo of 10 mg/dL or more, but only have a power of .70 
to detect a difference of 5 mg/dL. 
PHASES OF CLINICAL TRIALS 
Clinical trials involving new drugs are commonly classified into four 
phases. Each phase of the drug approval process is treated as a 
separate clinical trial. The drug-development process will normally 
proceed through all four phases over many years.  
If the drug successfully passes through Phases I, II, and III, it will 
usually be approved by the national regulatory authority for use in 
the general population. Phase IV are 'post-approval' studies. 
Before pharmaceutical companies start clinical trials on a drug, they 
conduct extensive pre-clinical studies. 
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Pre-clinical studies involve in vitro (test tube or cell culture) and in 
vivo (animal) experiments using wide-ranging doses of the study 
drug to obtain preliminary efficacy, toxicity and pharmacokinetic 
information. Such tests assist pharmaceutical companies to decide 
whether a drug candidate has scientific merit for further 
development as an investigational new drug. 
Phase 0 
Phase 0 is a recent designation for exploratory, first-in-human trials 
conducted in accordance with the United States Food and Drug 
Administration's (FDA) 2006 Guidance on Exploratory 
Investigational New Drug (IND) Studies.[21] 
Phase 0 trials are also known as human microdosing studies and are 
designed to speed up the development of promising drugs or 
imaging agents by establishing very early on whether the drug or 
agent behaves in human subjects as was expected from preclinical 
studies. 
Distinctive features of Phase 0 trials include the administration of 
single subtherapeutic doses of the study drug to a small number of 
subjects (10 to 15) to gather preliminary data on the agent's 
pharmacokinetics (how the body processes the drug) and 
pharmacodynamics (how the drug works in the body).[22] 
A Phase 0 study gives no data on safety or efficacy, being by 
definition a dose too low to cause any therapeutic effect. Drug 
development companies carry out Phase 0 studies to rank drug 
candidates in order to decide which has the best pharmacokinetic 
parameters in humans to take forward into further development. 
They enable go/no-go decisions to be based on relevant human 
models instead of relying on sometimes inconsistent animal data. 
Questions have been raised by experts about whether Phase 0 trials 
are useful, ethically acceptable, feasible, speed up the drug 
development process or save money, and whether there is room for 
improvement.[23] 
Phase I 
Phase I trials are the first stage of testing in human subjects. 
Normally, a small (20-100) group of healthy volunteers will be 
selected. This phase includes trials designed to assess the safety 
(pharmacovigilance), tolerability, pharmacokinetics, and 
pharmacodynamics of a drug. 
These trials are often conducted in an inpatient clinic, where the 
subject can be observed by full-time staff. The subject who receives 
the drug is usually observed until several half-lives of the drug have 
passed. Phase I trials also normally include dose-ranging, also called 
dose escalation, studies so that the appropriate dose for therapeutic 
use can be found. 
The tested range of doses will usually be a fraction of the dose that 
causes harm in animal testing. Phase I trials most often include 
healthy volunteers. However, there are some circumstances when 
real patients are used, such as patients who have terminal cancer or 
HIV and lack other treatment options. Volunteers are paid an 
inconvenience fee for their time spent in the volunteer centre. 
There are different kinds of Phase I trials 
 SAD: Single Ascending Dose studies are those in which small groups 
of subjects are given a single dose of the drug while they are 
observed and tested for a period of time. If they do not exhibit any 
adverse side effects, and the pharmacokinetic data is roughly in line 
with predicted safe values, the dose is escalated, and a new group of 
subjects is then given a higher dose. This is continued until pre-
calculated pharmacokinetic safety levels are reached, or intolerable 
side effects start showing up (at which point the drug is said to have 
reached the Maximum tolerated dose (MTD). 
 MAD: Multiple Ascending Dose studies are conducted to better 
understand the pharmacokinetics & pharmacodynamics of multiple 
doses of the drug. In these studies, a group of patients receives 
multiple low doses of the drug, while samples (of blood, and other 
fluids) are collected at various time points and analyzed to 
understand how the drug is processed within the body. The dose is 
subsequently escalated for further groups, up to a predetermined 
level. Food effect a short trial designed to investigate any differences 
in absorption of the drug by the body, caused by eating before the 
drug is given. These studies are usually run as a crossover study, 
with volunteers being given two identical doses of the drug on 
different occasions; one while fasted, and one after being fed. 
Phase II 
Once the initial safety of the study drug has been confirmed in Phase 
I trials, Phase II trials are performed on larger groups (20-300) and 
are designed to assess how well the drug works, as well as to 
continue Phase I safety assessments in a larger group of volunteers 
and patients. When the development process for a new drug fails, 
this usually occurs during Phase II trials when the drug is discovered 
not to work as planned, or to have toxic effects. 
Phase II studies are sometimes divided into Phase IIA and Phase IIB. 
Phase IIA is specifically designed to assess dosing requirements 
(how much drug should be given). 
Phase IIB is specifically designed to study efficacy (how well the 
drug works at the prescribed dose(s)). 
Some trials combine Phase I and Phase II, and test both efficacy and 
toxicity. 
 Trial design: Some Phase II trials are designed as case series, 
demonstrating a drug's safety and activity in a selected group of 
patients. Other Phase II trials are designed as randomized clinical 
trials, where some patients receive the drug/device and others 
receive placebo/standard treatment. Randomized Phase II trials 
have far fewer patients than randomized Phase III trials. 
Phase III 
Phase III studies are randomized controlled multicenter trials on 
large patient groups (300–3,000 or more depending upon the 
disease/medical condition studied) and are aimed at being the 
definitive assessment of how effective the drug is, in comparison 
with current 'gold standard' treatment. Because of their size and 
comparatively long duration, Phase III trials are the most expensive, 
time-consuming and difficult trials to design and run, especially in 
therapies for chronic medical conditions. 
It is common practice that certain Phase III trials will continue while 
the regulatory submission is pending at the appropriate regulatory 
agency.  
This allows patients to continue to receive possibly lifesaving drugs 
until the drug can be obtained by purchase. Other reasons for 
performing trials at this stage include attempts by the sponsor at 
"label expansion" (to show the drug works for additional types of 
patients/diseases beyond the original use for which the drug was 
approved for marketing), to obtain additional safety data, or to 
support marketing claims for the drug. Studies in this phase are by 
some companies categorised as "Phase IIIB studies."[24][25] While 
not required in all cases, it is typically expected that there be at least 
two successful Phase III trials, demonstrating a drug's safety and 
efficacy, in order to obtain approval from the appropriate regulatory 
agencies such as FDA (USA), or the EMA (European Union), for 
example. 
Once a drug has proved satisfactory after Phase III trials, the trial 
results are usually combined into a large document containing a 
comprehensive description of the methods and results of human and 
animal studies, manufacturing procedures, formulation details, and 
shelf life. This collection of information makes up the "regulatory 
submission" that is provided for review to the appropriate 
regulatory authorities [4] in different countries. They will review the 
submission, and, it is hoped, give the sponsor approval to market the 
drug. 
Most drugs undergoing Phase III clinical trials can be marketed 
under FDA norms with proper recommendations and guidelines, but 
in case of any adverse effects being reported anywhere, the drugs 
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need to be recalled immediately from the market. While most 
pharmaceutical companies refrain from this practice, it is not 
abnormal to see many drugs undergoing Phase III clinical trials in 
the market.[26] 
Phase IV 
Phase IV trial is also known as Post Marketing Surveillance Trial. 
Phase IV trials involve the safety surveillance (pharmacovigilance) 
and ongoing technical support of a drug after it receives permission 
to be sold. Phase IV studies may be required by regulatory 
authorities or may be undertaken by the sponsoring company for 
competitive (finding a new market for the drug) or other reasons 
(for example, the drug may not have been tested for interactions 
with other drugs, or on certain population groups such as pregnant 
women, who are unlikely to subject themselves to trials).  The safety 
surveillance is designed to detect any rare or long-term adverse 
effects over a much larger patient population and longer time period 
than was possible during the Phase I-III clinical trials. Harmful 
effects discovered by Phase IV trials may result in a drug being no 
longer sold, or restricted to certain uses: recent examples involve 
cerivastatin (brand names Baycol and Lipobay), troglitazone 
(Rezulin) and rofecoxib (Vioxx).
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Clinical trials designed by a local investigator and (in the U.S.) 
federally funded clinical trials are almost always administered by 
the researcher who designed the study and applied for the grant.  
Small-scale device studies may be administered by the sponsoring 
company. Phase III and Phase IV clinical trials of new drugs are 
usually administered by a contract research organization (CRO) 
hired by the sponsoring company. (The sponsor provides the drug 
and medical oversight.)  
A CRO is a company that is contracted to perform all the 
administrative work on a clinical trial. It recruits participating 
researchers, trains them, provides them with supplies, coordinates 
study administration and data collection, sets up meetings, monitors 
the sites for compliance with the clinical protocol, and ensures that 
the sponsor receives 'clean' data from every site.  
Recently, site management organizations have also been hired to 
coordinate with the CRO to ensure rapid IRB/IEC approval and 
faster site initiation and patient recruitment. 
At a participating site, one or more research assistants (often 
nurses) do most of the work in conducting the clinical trial.  
The research assistant's job can include some or all of the following: 
providing the local Institutional Review Board (IRB) with the 
documentation necessary to obtain its permission to conduct the 
study, assisting with study start-up, identifying eligible patients, 
obtaining consent from them or their families, administering study 
treatment(s), collecting and statistically analyzing data, maintaining 
and updating data files during followup, and communicating with 
the IRB, as well as the sponsor and CRO. 
ETHICAL CONDUCT OF CLINICAL TRIAL 
Clinical trials are closely supervised by appropriate regulatory 
authorities. All studies that involve a medical or therapeutic 
intervention on patients must be approved by a supervising ethics 
committee before permission is granted to run the trial. 
 The local ethics committee has discretion on how it will supervise 
noninterventional studies (observational studies or those using 
already collected data). In the U.S., this body is called the 
Institutional Review Board (IRB). Most IRBs are located at the local 
investigator's hospital or institution, but some sponsors allow the 
use of a central (independent/for profit) IRB for investigators who 
work at smaller institutions. 
To be ethical, researchers must obtain the full and informed consent 
of participating human subjects. (One of the IRB's main functions is 
ensuring that potential patients are adequately informed about the 
clinical trial.)  
If the patient is unable to consent for him/herself, researchers can 
seek consent from the patient's legally authorized representative. In 
California, the state has prioritized the individuals who can serve as 
the legally authorized representative.In some U.S. locations, the local 
IRB must certify researchers and their staff before they can conduct 
clinical trials.  
They must understand the federal patient privacy (HIPAA) law and 
good clinical practice. International Conference of Harmonisation 
Guidelines for Good Clinical Practice (ICH GCP) is a set of standards 
used internationally for the conduct of clinical trials. The guidelines 
aim to ensure that the "rights, safety and well being of trial subjects 
are protected". The notion of informed consent of participating 
human subjects exists in many countries all over the world, but its 
precise definition may still vary. 
Informed consent is clearly a necessary condition for ethical conduct 
but does not ensure ethical conduct. The final objective is to serve 
the community of patients or future patients in a best-possible and 
most responsible way. However, it may be hard to turn this objective 
into a well-defined quantified objective function. In some cases this 
can be done, however, as for instance for questions of when to stop 
sequential treatments (see Odds algorithm), and then quantified 
methods may play an important role.Additional ethical concerns are 
present when conducting clinical trials on children (pediatrics). 
Ethical guidelines for biomedical research 
As of January 2005, biomedical research in India must comply with 
the ethical principles laid out in the World Medical Association 
Declaration of Helsinki. It must also follow the the Indian Council of 
Medical Research’s ethical guidelines for biomedical research on 
humans. 
World Medical Association Declaration of Helsinki 
The Declaration of Helsinki is accepted as an international standard 
for biomedical research. The Declaration has been revised a number 
of times since it was first adopted by the World Medical 
Association’s General Assembly in June 1964. The Declaration of 
Helsinki was last revised on October 22, 200825 and is the relevant 
document for ongoing and future research. The trials described in 
this report took place between 2002 and 2006. The following 
paragraphs, on research among vulnerable groups, the informed 
consent process, the use of placebo controls and the benefits of 
research are particularly relevant in these trials.  
The economically and medically disadvantaged need special 
protection: Medical research is subject to ethical standards that 
promote respect for all human beings and protect their health and 
rights. Some research populations are vulnerable and need special 
protection. The particular needs of the economically and medically 
disadvantaged must be recognized. Special attention is also required 
for those who cannot give or refuse consent for themselves, for those 
who may be subject to giving consent under duress, for those who 
will not benefit personally from the research and for those for whom 
the research is combined with care.  
Investigator/physicians recruiting their patients into a clinical trial 
must be careful not to exercise undue influence: When obtaining 
informed consent for the research project the physician should be 
particularly cautious if the subject is in a dependent relationship 
with the physician or may consent under duress. In that case the 
informed consent should be obtained by a wellinformed physician 
who is not engaged in the investigation and who is completely 
independent of this relationship.  
Placebos or sugar pills should not be used when testing new drugs if 
an effective treatment for that condition already exists: The benefits, 
risks, burdens and effectiveness of a new method should be tested 
against those of the best current prophylactic, diagnostic, and 
therapeutic methods. This does not exclude the use of placebo, or no 
treatment, in studies where no proven prophylactic, diagnostic or 
therapeutic method exists.25 World Medical Association Declaration 
of Helsinki. Ethical principles for medical research involving human 
subjects. Adopted by the WMA General Assembly, Helsinki, Finland, 
June 1964 and lastamended at the 59th WMA Assembly, Seoul, 
October 2008. Available from: Ethical concerns in clinical trials in 
India: an investigation 
The Indian Council of Medical Research’s ethical guidelines 
onbiomedical research on humans 
As of January 2005, it is mandatory for clinical trials in India to 
conform to the ICMR’sguidelines and to the guidelines in the 
Declaration of Helsinki. The Indian Council of Medical Research’s 
guidelines were first published in 200026 and this version of the 
guidelines would have been applicable for the trials described in this 
report. The revised guidelines were published in 200627 and are the 
relevant guidelines for ongoing and future research. The guidelines 
state that: “persons who are economically or socially disadvantaged 
should not be used to benefit those who are better off than them.” 
(Section III iii b in ICMR, 2000; 27 Indian Council of Medical 
Research. Ethical guidelines for biomedical research on human 
participants. New Delhi: ICMR; 2006. Available from: Ethical 
concerns in clinical trials in India: an investigation  ‘Any research 
using the [sic] human beings should be selected so that burdens and 
benefits of the research are distributed without arbitrariness, 
discrimination or caprice.” Research should abide by the principles 
of “maximisation of the public interest and of distributive justice 
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whereby, the research or experiment and its subsequent applicative 
use are conducted and used to benefit all humankind and not just 
those who are socially better off but also the least advantaged; and 
in particular the research subject themselves. 
SAFETY OF CLINICAL TRIAL 
Responsibility for the safety of the subjects in a clinical trial is 
shared between the sponsor, the local site investigators (if different 
from the sponsor), the various IRBs that supervise the study, and (in 
some cases, if the study involves a marketable drug or device) the 
regulatory agency for the country where the drug or device will be 
sold. 
For safety reasons, many clinical trials of drugs are designed to 
exclude women of childbearing age, pregnant women, and/or 
women who become pregnant during the study. In some cases the 
male partners of these women are also excluded or required to take 
birth control measures. 
Sponsor 
Throughout the clinical trial, the sponsor is responsible for 
accurately informing the local site investigators of the true historical 
safety record of the drug, device or other medical treatments to be 
tested, and of any potential interactions of the study treatment(s) 
with already approved medical treatments. This allows the local 
investigators to make an informed judgment on whether to 
participate in the study or not. The sponsor is responsible for 
monitoring the results of the study as they come in from the various 
sites, as the trial proceeds. In larger clinical trials, a sponsor will use 
the services of a Data Monitoring Committee (DMC, known in the 
U.S. as a Data Safety Monitoring Board). This is an independent 
group of clinicians and statisticians.  
 
The DMC meets periodically to review the unblinded data that the 
sponsor has received so far. The DMC has the power to recommend 
termination of the study based on their review, for example if the 
study treatment is causing more deaths than the standard treatment, 
or seems to be causing unexpected and study-related serious 
adverse events. 
The sponsor is responsible for collecting adverse event reports from 
all site investigators in the study, and for informing all the 
investigators of the sponsor's judgment as to whether these adverse 
events were related or not related to the study treatment. This is an 
area where sponsors can slant their judgment to favor the study 
treatment. 
The sponsor and the local site investigators are jointly responsible 
for writing a site-specific informed consent that accurately informs 
the potential subjects of the true risks and potential benefits of 
participating in the study, while at the same time presenting the 
material as briefly as possible and in ordinary language.  
FDA regulations and ICH guidelines both require that “the 
information that is given to the subject or the representative shall be 
in language understandable to the subject or the representative." If 
the participant's native language is not English, the sponsor must 
translate the informed consent into the language of the 
participant.[30] 
Local site investigators 
A physician's first duty is to his/her patients, and if a physician 
investigator believes that the study treatment may be harming 
subjects in the study, the investigator can stop participating at any 
time. On the other hand, investigators often have a financial interest 
in recruiting subjects, and can act unethically in order to obtain and 
maintain their participation. The local investigators are responsible 
for conducting the study according to the study protocol, and 
supervising the study staff throughout the duration of the study.The 
local investigator or his/her study staff are responsible for ensuring 
that potential subjects in the study understand the risks and 
potential benefits of participating in the study; in other words, that 
they (or their legally authorized representatives) give truly informed 
consent. 
The local investigators are responsible for reviewing all adverse 
event reports sent by the sponsor. (These adverse event reports 
contain the opinion of both the investigator at the site where the 
adverse event occurred, and the sponsor, regarding the relationship 
of the adverse event to the study treatments).  
The local investigators are responsible for making an independent 
judgment of these reports, and promptly informing the local IRB of 
all serious and study-treatment-related adverse events. When a local 
investigator is the sponsor, there may not be formal adverse event 
reports, but study staff at all locations are responsible for informing 
the coordinating investigator of anything unexpected.NThe local 
investigator is responsible for being truthful to the local IRB in all 
communications relating to the study. 
IRB 
Approval by an IRB, or ethics board, is necessary before all but the 
most informal medical research can begin. In commercial clinical 
trials, the study protocol is not approved by an IRB before the 
sponsor recruits sites to conduct the trial.  However, the study 
protocol and procedures have been tailored to fit generic IRB 
submission requirements.  
In this case, and where there is no independent sponsor, each local 
site investigator submits the study protocol, the consent(s), the data 
collection forms, and supporting documentation to the local IRB. 
Universities and most hospitals have in-house IRBs. Other 
researchers (such as in walk-in clinics) use independent IRBs. The 
IRB scrutinizes the study for both medical safety and protection of 
the patients involved in the study, before it allows the researcher to 
begin the study.  It may require changes in study procedures or in 
the explanations given to the patient.  A required yearly "continuing 
review" report from the investigator updates the IRB on the 
progress of the study and any new safety information related to the 
study. 
Regulatory agencies 
If a clinical trial concerns a new regulated drug or medical device (or 
an existing drug for a new purpose), the appropriate regulatory 
agency for each country where the sponsor wishes to sell the drug or 
device is supposed to review all study data before allowing the 
drug/device to proceed to the next phase, or to be marketed. 
However, if the sponsor withholds negative data, or misrepresents 
data it has acquired from clinical trials, the regulatory agency may 
make the wrong decision. 
In the U.S., the FDA can audit the files of local site investigators after 
they have finished participating in a study, to see if they were 
correctly following study procedures.  This audit may be random, or 
for cause (because the investigator is suspected of fraudulent data). 
Avoiding an audit is an incentive for investigators to follow study 
procedures. Different countries have different regulatory 
requirements and enforcement abilities. "An estimated 40 percent of 
all clinical trials now take place in Asia, Eastern Europe, central and 
south America.  “There is no compulsory registration system for 
clinical trials in these countries and many do not follow European 
directives in their operations”, says Dr. Jacob Sijtsma of the 
Netherlands-based WEMOS, an advocacy health organisation 
tracking clinical trials in developing countries." [31] 
Accidents 
In March 2006 the drug TGN1412 caused catastrophic systemic 
organ failure in the individuals receiving the drug during its first 
human clinical trials (Phase I) in Great Britain.  Following this, an 
Expert Group on Phase One Clinical Trials published a report.[32] 
Investigational drug Trovan was tested on children in Nigeria 
causing severe health problems leading to lawsuits.[33] In May 
2010, a Phase III clinical trial for rheumatoid arthritis using 
ocrelizumab, an investigational new drug sponsored by Roche and 
Biogen Idec, was shut down after an excess number of deaths due to 
opportunistic infections in the interventional arm of the study.[34]  
In October 2010, a Phase II trial for multiple sclerosis using the same 
drug was shut down after a patient died from systemic inflammatory 
response syndrome while taking the drug.[35][36] 
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ECONOMICS AND PARTICIPATING IN CLINICAL TRIAL 
Sponsor 
The cost of a study depends on many factors, especially the number 
of sites that are conducting the study, the number of patients 
required, and whether the study treatment is already approved for 
medical use. Clinical trials follow a standardized process. 
 
The costs to a pharmaceutical company of administering a Phase III 
or IV clinical trial may include, among others: 
 manufacturing the drug(s)/device(s) tested 
 staff salaries for the designers and administrators of the trial 
 payments to the contract research organization, the site 
management organization (if used) and any outside 
consultants 
 payments to local researchers (and their staffs) for their 
time and effort in recruiting patients and collecting data for 
the sponsor 
 study materials and shipping 
 communication with the local researchers, including onsite 
monitoring by the CRO before and (in some cases) multiple 
times during the study 
 one or more investigator training meetings 
 costs incurred by the local researchers such as pharmacy 
fees, IRB fees and postage. 
 any payments to patients enrolled in the trial (all payments 
are strictly overseen by the IRBs to ensure that patients do 
not feel coerced to take part in the trial by overly attractive 
payments) 
In the U.S. there is a 50% tax credit for sponsors of certain clinical 
trials.[37] National health agencies such as the U.S. National 
Institutes of Health offer grants to investigators who design clinical 
trials that attempt to answer research questions that interest the 
agency.  In these cases, the investigator who writes the grant and 
administers the study acts as the sponsor, and coordinates data 
collection from any other sites.  These other sites may or may not be 
paid for participating in the study, depending on the amount of the 
grant and the amount of effort expected from them. Clinical trials are 
traditionally expensive and difficult to undertake. Using internet 
resources can, in some cases, reduce the economic burden.[38] 
Investigators 
Many clinical trials do not involve any money. However, when the 
sponsor is a private company or a national health agency, 
investigators are almost always paid to participate. These amounts 
can be small, just covering a partial salary for research assistants 
and the cost of any supplies (usually the case with national health 
agency studies), or be substantial and include 'overhead' that allows 
the investigator to pay the research staff during times in between 
clinical trials. 
Patients 
In Phase I drug trials, participants are paid because they give up 
their time (sometimes away from their homes) and are exposed to 
unknown risks, without the expectation of any benefit. In most other 
trials, however, patients are not paid, in order to ensure that their 
motivation for participating is the hope of getting better or 
contributing to medical knowledge, without their judgment being 
skewed by financial considerations. However, they are often given 
small payments for study-related expenses like travel or as 
compensation for their time in providing follow-up information 
about their health after they are discharged from medical care. 
Participating in a clinical trial 
Newspaper advertisements seeking patients and healthy volunteers 
to participate in clinical trials.Phase 0 and Phase I drug trials seek 
healthy volunteers. Most other clinical trials seek patients who have 
a specific disease or medical condition. 
Locating trials 
Depending on the kind of participants required, sponsors of clinical 
trials use various recruitment strategies, including patient 
databases, newspaper and radio advertisements, flyers, posters in 
places the patients might go (such as doctor's offices), and personal 
recruitment of patients by investigators.Volunteers with specific 
conditions or diseases have additional online resources to help them 
locate clinical trials.  
For example, people with Parkinson's disease can use PDtrials to 
find up-to-date information on Parkinson's disease trials currently 
enrolling participants in the U.S. and Canada, and search for specific 
Parkinson’s clinical trials using criteria such as location, trial type, 
and symptom.[39] Other disease-specific services exist for 
volunteers to find trials related to their condition.[40] Volunteers 
may also search directly on ClinicalTrials.gov to locate trials using a 
registry run by the U.S. National Institutes of Health and National 
Library of Medicine. However, many clinical trials will not accept 
participants who contact them directly to volunteer as it is believed 
this may bias the characteristics of the population being studied. 
Such trials typically recruit via networks of medical professionals 
who ask their individual patients to consider enrollment.[citation 
needed] 
Steps for volunteers 
Before participating in a clinical trial, interested volunteers should 
speak with their doctors, family members, and others who have 
participated in trials in the past. After locating a trial, volunteers will 
often have the opportunity to speak or e-mail the clinical trial 
coordinator for more information and to answer any questions. After 
receiving consent from their doctors, volunteers then arrange an 
appointment for a screening visit with the trial coordinator.[41] 
All volunteers being considered for a trial are required to undertake 
a medical screen. There are different requirements for different 
trials, but typically volunteers will have the following tests:[42] 
 Measurement of the electrical activity of the heart (ECG) 
 Measurement of blood pressure, heart rate and temperature 
 Blood sampling 
 Urine sampling 
 Weight and height measurement 
 Drugs abuse testing 
 Pregnancy testing (females only) 
INFORMATION TECHNOLOGY IN CLINICAL TRIAL 
The last decade has seen a proliferation of information technology 
use in the planning and conduct of clinical trials. Clinical trial 
management systems (CTMS) are often used by research sponsors 
or CROs to help plan and manage the operational aspects of a clinical 
trial, particularly with respect to investigational sites. 
Web-based electronic data capture (EDC) and clinical data 
management systems (CDMS) are used in a majority of clinical trials 
[43] to collect case report data from sites, manage its quality and 
prepare it for analysis.  
Interactive voice response systems (IVRS) are used by sites to 
register the enrollment of patients using a phone and to allocate 
patients to a particular treatment arm (although phones are being 
increasingly replaced with web-based tools which are sometimes 
part of the EDC system).  Patient-reported outcome measures are 
being increasingly collected using hand-held, sometimes wireless 
ePRO (or eDiary) devices. 
Statistical software is used to analyze the collected data and prepare 
it for regulatory submission.  Access to many of these applications 
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Clinical Trial Experiance 
 
 
CRITICISM OF CLINIAL TRIAL 
Marcia Angell has been a stern critic of U.S. health care in general 
and the pharmaceutical industry in particular. She is scathing on the 
topic of how clinical trials are conducted in America:Many drugs that 
are assumed to be effective are probably little better than placebos, 
but there is no way to know because negative results are hidden.... 
Because favorable results were published and unfavorable results 
buried ... the public and the medical profession believed these drugs 
were potent.... Clinical trials are also biased through designs for 
research that are chosen to yield favorable results for sponsors. For 
example, the sponsor's drug may be compared with another drug 
administered at a dose so low that the sponsor's drug looks more 
powerful.  
Or a drug that is likely to be used by older people will be tested in 
young people, so that side effects are less likely to emerge. A 
common form of bias stems from the standard practice of comparing 
a new drug with a placebo, when the relevant question is how it 
compares with an existing drug.  
In short, it is often possible to make clinical trials come out pretty 
much any way you want, which is why it's so important that 
investigators be truly disinterested in the outcome of their work.... It 
is simply no longer possible to believe much of the clinical research 
that is published, or to rely on the judgment of trusted physicians or 
authoritative medical guidelines. I take no pleasure in this 
conclusion, which I reached slowly and reluctantly over my two 
decades as an editor of the New England Journal of Medicine.[44] 
Angell believes that members of medical school faculties who 
conduct clinical trials should not accept any payments from drug 
companies except research support, and that support should have 
no strings attached, including control by the companies over the 
design, interpretation, and publication of research results.She has 
speculated that "perhaps most" of the clinical trials are viewed by 
critics as "excuses to pay doctors to put patients on a company's 
already-approved drug".[45]  
CLINIAL TRIALS IN INDIA 
The larger context of clinical trials in India is poverty and the 
absence of affordable healthcare. For more than a decade, 
government policy has been to reduce public support for healthcare 
services, and these services are under-resourced. Health economists 
have pointed out that only 15 per cent of the Rs 1,500 billion spent 
in the health sector in India comes from the government. Four per 
cent comes from social insurance and one per cent from private 
insurance companies. The remaining 80 per cent is spent by 
individuals using private services and without insurance.  
 
 
Two-thirds of health care users bear 100 per cent of their health 
care expenses. Seventy per cent of these health care users are poor. 
More than half of the poorest 20 per cent of Indians sold assets or 
borrowed to pay for health care4. Patients in both government 
hospitals and private hospitals are desperate for better quality and 
affordable care. Patients choose public hospitals because they 
cannot afford treatment in private hospitals but even here they pay 
for some drugs, tests and procedures, and this constitutes a burden 
that many cannot afford. The vast majority of Indians must pay for 
medical treatment from their own resources.  
Patients in private hospitals are more able to afford treatment but 
catastrophic medical expenses can force them to sell assets, go into 
debt, or stop essential treatment. Various surveys have found that 
medical expenses are a major factor forcing many Indians below the 
poverty line5.In this situation, government moves to encourage 
clinical trials in India must be viewed with concern. Changes have 
been made in the law to permit international trials. Staff and 
infrastructure improvements and regulatory changes are meant to 
speed up processing of applications.  
Public hospitals are being promoted as clinical trial sites. Monitoring 
systems are being set up to ensure high data quality and meet the 
requirements of drug regulatory authorities abroad. Training 
institutes are being encouraged to provide the humanpower to run 
clinical trials. The government has not expressed a stand on the 
manner in which the clinical research industry is growing in India. 
Clinical trials are conducted by contract research organizations 
(CROs) which are developing the infrastructure for trials by making 
inroads into small towns, identifying trial sites in small private 
hospitals and developing databases of potential trial participants.  
Medical professionals are given substantial incentives to recruit 
their own patients into clinical trials. This situation creates a major 
conflict of interest that threatens the well-being of patients. India is 
viewed as a favoured global site for international clinical trials of 
drugs. According to the Drugs Controller General of India (DCGI), 
India will be a preferred site for clinical trials because, in addition to 
its medical infrastructure and trained, English speaking 
humanpower,  
it has a “large, diverse and treatment-naïve [untreated] population 
with six out of the seven genetic varieties of the human race”; a pool 
of patients with both acute and chronic diseases, an increase in the 
number of patients with lifestyle disorders and the highest 
recruitment rates for such trials internationally6. The Indian 
government has seized upon this opportunity and is taking steps to 
change the regulatory climate here to accommodate the needs of 
international clinical trials. 
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Regulation of clinical trials 
Clinical trials in India are regulated by Schedule Y of the Drugs and 
Cosmetics Rules. The Rules are enforced by the office of the DCGI 
who is also responsible for monitoring all clinical trials submitted to 
that office for approval. For new drugs being developed in India 
clinical trials have to be conducted in India from phase 1. 
For marketing approval of drugs already approved in other 
countries, a phase 3 clinical trial is required on about 100 patients in 
three or more centres, in order to establish the drug’s impact on the 
Indian ethnic population. An application for a new indication of an 
already approved drug is treated as an application for a new drug’s 
approval.  
New formulations of approved drugs may be subjected to 
bioequivalence studies. Till January 2005, clinical trials of new drugs 
being developed outside India were permitted only with a “phase 
lag”: a phase 2 trial could be conducted in India only after phase 3 
trials were completed elsewhere.  
Phase 1 trials of foreign drugs were not permitted, except for drugs 
of special relevance to India. This clause enabled, for example, phase 
1 trials of HIV vaccines in India. In fact, international multicentre 
trials have been conducted in India since the mid-1990s9. 
Phase 2 and phase 3 trials of drugs discovered abroad may now be 
conducted in India in the same phase and at the same time as they 
are conducted in other parts of the world. The trial sponsor must 
obtain approval from the DCGI before starting a trial. For this 
approval, the sponsor must submit data from pharmacokinetic and 
animal studies and previous phase trials; information on the 
regulatory status of the drug in other countries, the trial protocol, 
investigator’s brochures and informed consent documents. Trials 
cannot be started without clearance from the local ethics review 
committee (EC) at each site. 
Phase II trials evaluate the effectiveness and safety of a drug on 
patients. Phase III trials are conducted on larger numbers of people 
to confirm the evidence from earlier phase trials towards obtaining 
marketing approval of the drug.  
Phase IV trials are conducted after a drug obtains marketing 
approval. They are conducted for various purposes including 
monitoring for drug interactions and testing for new uses of the 
drug.  
Government steps to promote clinical trials 
At a meeting of the Institute of Clinical Research [India] (ICRI) in 
Mumbai, Surinder Singh, Drugs Controller General of India, 
described a number of other steps that the government plans to 
undertake towards encouraging international clinical trials in 
India16. In addition to changes in the law (that have already taken 
effect), single window clearance for applications is planned in order 
to reduce the approval procedure to between two and six weeks. 
 A two-tier approval process is already in place. Category A protocols 
consist of protocols from the US, United Kingdom (UK), EU and 
Japan. Category A trials will get fast track approval of six to eight 
weeks. Category B trials from other countries will get approval in 
eight to 12 weeks. The government will grant a license to import 
supplies within two weeks of the application being made. The DCGI 
has also promised that local EC review will be completed in six to 
eight weeks. By 2009, he said, timelines will be in harmony with 
international clinical trials. The DCGI announced plans to recruit 
subject experts and has also got approval for 60 new drug 
inspectors. 20 of these inspectors will be responsible exclusively for 
auditing clinical trials. 
Trends in international clinical research in India 
International clinical trials have been conducted in India starting in 
the mid 1990s though it was only in 2005 that regulations were 
changed to routinely enable concurrent phase trials. The DCGI has 
stated that there are 582 (registered) clinical trials being conducted 
in India, of which 72 per cent are conducted by the pharmaceutical 
industry17. (A search in October 2008 of www.clinicaltrials.gov for 
trials with a site in India lists 789 studies, planned, recruiting 
terminated and completed.) 
 
Contract research organizations 
Drug companies conduct clinical trials through contract research 
organizations (CROs), commercial entitites whose job it is to get the 
research done and to meet regulatory requirements. Since the early 
2000s, there seems to have been a sharp rise in the number of 
contract research organisations functioning in India; the DCGI has 
stated that the estimated number of contract research organisations 
in India registered with the USFDA has gone from 60 to 150. CROs 
may handle some or all aspects of a sponsor’s project including: 
regulatory approvals for trials, identifying recruiting sites and 
investigators, monitoring sites, data entry and management, 
submitting data for marketing approval and drafting study reports 
for submission to journals. These activities may also be split up and 
handled by different organizations. Some organizations focus 
exclusively on providing data management and statistical analysis. 
Trial sites that do not have institutional review boards may 
approach “stand alone” ethics committees not affiliated to any 
institution. Site maintenance organizations (SMOs) are focused 
exclusively on recruiting patients and coordinating the work of 
investigators conducting clinical trials18. 
Why do people participate in clinical trials? 
A CRO-conducted survey of the informed consent process in clinical 
trials provides some interesting information on the patient 
recruitment procedure and the quality of informed consent in 
clinical trials in India20. This survey was of patients participating in 
trials run by the 17 Surinder Singh, Drugs Controller General of 
India, at a conference of the Institute of Clinical Research (India), 
Mumbai, October 10-11, 2008. 
They may also believe that refusal to follow the doctor’s advice to 
enter a trial would affecttheir access to care. When the trial’s 
principal investigator is also the person’s primary physician, there is 
scope for a direct conflict of interest, especially if physicians are paid 
recruitment fees to recruit their patients into trials. The survey’s 
findings on why people entered a clinical trial were enlightening: 
 15 per cent stated that they entered the trial because they 
were looking for a cure. 
 13 per cent were looking for “observed benefits”. 
 15 per cent were looking for a better treatment. 
 16 per cent were looking for higher quality care. 
 10 per cent were looking for free medication and medical 
care. 
 15 per cent said the doctor advised them to enter the trial. 
 5 per cent said they entered the trial to receive money for 
participation. 
 11 per cent said they entered the trial to help advance 
scientific knowledge. 
Some of the categories – such as “observed benefits” – are not clearly 
described. However, it is a matter of concern that 26 per cent of 
participants stated that they entered the trial to obtain free care or 
higher quality care. It is quite possible that such patients overlook 
risks to participate in trials. Another 15 per cent stated that they 
were following their doctor’s advice – a possible concern if their 
doctor received fees to recruit them into the trial. The five per cent 
who entered the trial to receive money for participation are very 
likely to have overlooked the risks of participation. 
According to the ICMR’s guidelines, “… payments should not be so 
large or the medical services so extensive as to make prospective 
participants consent readily to enroll in research against their better 
judgment, which would then be treated as undue inducement.” 
However, patients in bioequivalence trials (used to check that 
generic versions of approved drugs or for new formulations of 
approved drugs work as well as the approved drug) may have paid 
up to Rs 20,000 to participate in the trial. 
Incentives for clinical trial investigators 
When the government declared its plans to use government 
hospitals as clinical trial sites21, government institutions were 
already the sites for many clinical trials. Public hospitals are 
resource-starved (the per capita expenditure on health was $100 in 
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2005, of which less than 20 per cent was by the government22. In 
2002, public expenditure on health was less than one per cent of the 
Gross Domestic Product23 and this percentage has not changed 
since then). Patients at public hospitals are often forced to go to 
private centers and pay for basic tests, drugs and supplies. 
Government doctors running trial sites do not officially receive fees 
for recruiting patients into clinical trials. A CRO with a trial site in a 
government institution will pay about 15 per cent of the budgeted 
expenses for that site directly to the institution. 
The hospital department running a trial site gains some equipment 
and the salaries of junior/additional investigators are paid by the 
trial sponsor for the duration of the trial. Administrators and senior 
staff at government hospitals may view clinical trials as helping the 
work of an under-resourced hospital. Principal investigators also get 
invited to all-expenses paid conferences abroad. For government 
doctors, such trips may be enough incentive to conduct trials, even 
without recruitment fees. The incentives to investigators in private 
hospitals are more upfront; the investigator is paid according to the 
number of patients recruited (additional benefits include all-
expenses paid trips abroad to attend conferences). 
Appendix I 
Contact and correspondence with investigators and institutions 
Contact with trial investigators 
Shona Nag and Dinesh Doval were interviewed at their offices about 
the lapatinib trial. The third Indian investigator in the lapatinib trial 
could not be contacted. In the psychiatric drug trials, efforts were 
made to contact all the researchers in the three trials. The director of 
the National Institute for Mental Health and Neurosciences, one of 
the sites for the risperidone study was sent an e-mail asking for an 
interview. Face to face interviews were conducted with Jitendra 
Trivedi and Sumant Khanna.  
A second interview with Dr Khanna was conducted on the telephone. 
Telephone interviews were conducted with Kurien Kuruvilla, R 
Sathianathan, V Debsikdar, and Prasad Rao. Podila Sharma and G K 
Vankar were sent a list of questions by e-mail. Dr Sharma 
acknowledged the e-mail. Shiv Gautam was contacted but could not 
be interviewed. R Palaniappan, J Nagpal and Nagesh Pai were not 
contactable. Dr Pai has reportedly migrated to Australia. 
The following were sent an e-mail with the quoted statements, 
informing them that they were being quoted: Shona Nag, Dinesh 
Doval, Prasad Rao, Jitendra Trivedi, Sumant Khanna, R Sathianathan 
and V Debsikdar. Dr Debsikdar’s e-mail obtained from his residence 
bounced back. Dr Kuruvilla was phoned for his e-mail address but 
did not give it on the phone and then refused to answer phone calls. 
Dr Nag, Dr Doval, Dr Khanna and Dr Trivedi gave their consent to 
their statements quoted in this report. 
Appendix II 
Contact and correspondence with the companies  
During the shortlisting of trials, efforts were made to obtain an 
interview from the  companiesconducting the trials. Two of the five 
companies (Eli Lilly, manufacturing exenatide, and Nycomed 
Pharma, manufacturing ciclesonide) responded stating that they 
would not provide any information. After the interviews with 
investigators in the four trials, efforts were made to contact a 
representative in the three companies, GlaxoSmithKline, Johnson & 
Johnson and AstraZeneca. Following this second round of telephonic 
contact, e-mails were sent to the the medical director of 
GlaxoSmithKline, Mumbai, the director (corporate communications), 
Johnson & Johnson, Mumbai and the director (corporate 
communications), Astra Zeneca, Bangalore. These letters were also 
delivered by courier. 
The letters asked for details on the trials including the number of 
patients recruited at each site, economic background of patients and 
the information given to patients. A copy of the informed consent 
form, regulatory approval and details of the local ethics committee 
were also sought. Efforts to speak to the the director (corporate 
communications), Astra Zeneca, were fruitless and the company did 
not respond to were did not respond to e-mails sent to the e-mail 
company address or to Sheshendra Bhadauria, the director, 
corporate communications, whose name and e-mail address were 
obtained from the Bangalore head office.  
Appendix III 
Summary of the process identifying four drug trials for investigation 
In the first stage of this work, various searches were conducted of 
the database www.clinicaltrials.gov using the keywords India, 
placebo control, mania, schizophrenia and depression, to identify 
ongoing trials with India sites whose trial design was likely to be of 
concern. This was not meant to provide an objective list, or a list that 
allowed for generalisability, as the objective of the study was only to 
document types of unethical research practices. After a discussion 
with Wemos and SOMO, it was decided that while a search for 
ongoing trials would be important, the objective of highlighting 
concerns in drugs approved for the EU would best be served by 
looking at completed trials that might have been used for approval 
by the European Medicines Agency (EMEA). The rest of the work 
was based on a shortlist sent by SOMO of trials with at least one site 
in India, and related to drugs that had been approved in the EU after 
2004.  
The trials were: four placebo-controlled phase 3 trials of quetiapine, 
a psychiatric drug marketed by Astra Zeneca; 
Three phase 2 trials of lapatinib, a drug for breast cancer marketed 
by Glaxo Smithkline; 
three phase 3 trials of ciclesonide, an inhaled steroid for asthma 
marketed by Nycomed Pharma/ Altana Pharma; one phase 3 trial of 
pregabalin for neuropathic pain marketed by Pfizer,one phase 3 trial 
of exenatide, an injectable drug for diabetes marketed by Eli Lilly, 
and one phase 3 trial of amlopidine/atovorstatin, a combination 
drug for hypertension andhigh cholesterol marketed by Eli Lilly. In 
the first stage, available information was assembled about the trials: 
journal publications and other results obtained through 
www.ClinicalTrialResults.org, the company sites, and google 
searches of the trial titles. 
The India offices of the companies  were contacted by phone and e-
mail, The representative of each company was informed that that we 
(Sandhya Srinivasan and Sachin Nikarge) were researchers with the 
Centre for Studies in Ethics and Rights and were interested in 
learning more about a trial of a drug manufactured by the company. 
The details sought were: the sites where the trial was conducted; the 
start and end dates of the trial; contact details of the institutions; the 
name of the CRO if one was involved; the names and contact details 
of the principal investigator, and membership and contact details of 
the ethics committee that reviewed the trial protocol. The 
representative of Eli Lilly (exenatide) replied on the telephone, 
refusing to provide details. The representative of Nycomed Pharma 
(ciclesonide) asked for an e-mail to be sent to the head office in 
Germany. Dr Christian Biberger, Director Clinical Trial Management 
Astra Zeneca, Eli Lilly, Pfizer, Altana Pharma and Glaxo Smith 
Kline.he letter delivered by courier. 
UNETHICAL TRIALS IN INDIA 
This briefing paper provides an overview of known examples of 
unethical clinical trials. It was prepared by SOMO, in collaboration 
with Wemos, and is based on secondary sources. Although the focus 
is on developing countries, it also includes a few cases from the US 
and Europe. By providing such an overview, the paper aims to 
illustrate problems in the ethical conduct of clinical trials. It does not 
provide an analysis of clinical trials in general or of the scale of 
ethical violations. Indeed, the scale of the problem is unknown, 
because it cannot be estimated how many unethical clinical trials 
escape public attention and therefore remain unnoticed.  
There are some indications that underlying structural problems 
exist, though, as in several of the trials described in this paper, the 
operations of pharmaceutical research companies were not 
adequately controlled or authorities seemed unwilling to address 
unethical drug testing even after it caught media attention. 
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This overview is limited to clinical trials involving drugs and 
vaccines, as such recent controversies about trials of the Dutch 
company Occam in India involving stents, or circumcision trials or 
circumcision trials in Africa, have been excluded. Furthermore, the 
focus is on ethical issues related to the design and conduct of trials. 
Conflicts about intellectual property or illegal exports of blood 
samples are not described. For each trial, selected information 
sources are provided. Most sources are publicly accessible websites, 
but some require a subscription.  The first version of this briefing 
was published in November 2006.  
The present version, which is the second update, does not include 
new cases but adds more recent developments on several trials, 
takes into account feedback from three companies, and has updated 
sources. For each trial, selected information sources are provided. 
Most sources are publicly accessible websites, but some require a 
subscription.  The first version of this briefing was published in 
November 2006. 
Ethical norms  
The case descriptions also refer to norms in widely accepted 
international codes that have (probably) been violated. The most 
cited reference is the Declaration of Helsinki (DoH) of the World 
Medical Association (WMA). European regulations specify that the 
trials providing the underlying data for marketing applications of 
new drugs need to comply with the Declaration of Helsinki. The 
World Health Organization (WHO) Guidelines for Good Clinical 
Practice (GCP) for trials on pharmaceutical products also endorses 
the DoH as the accepted basis for clinical trial ethics. Some 
important paragraphs from the declaration are briefly summarized 
below.  
As placebo-controlled clinical trials (DoH §29) are currently a 
standard practice rather than an exception (for phase III studies), 
this overview does not include trials that could be considered 
controversial solely because drugs were tested against placebos 
where proven alternatives already existed. Some examples of trials 
with controversial use of placebos can be found in:  Furthermore, 
despite recent initiatives to increase transparency about drug trials, 
the design of most studies is still not publicly available (DoH §16). 
Therefore this principle was also not used as a selection criterion for 
the overview of unethical clinical trials in this  
General observations  
Even though the overview below is necessarily incomplete and 
biased towards unethical trials that have caught some publicity, 
some general observations can still be made. Firstly, unethical trials 
have occurred around the world, in both developed and developing 
countries. In some cases, the trials had not been approved by an 
ethical review committee or institutional review board, or approval 
had be given for an unethical trial design. Hence there appear to be 
flaws, and sometimes rather serious ones, in the regulatory systems 
of various countries.  
Secondly, the research organizations involved range from relatively 
unknown local companies to leading multinational corporations. 
This might be surprising, given that large multinational corporations 
usually have clear public commitments to high ethical standards in 
clinical trials.  
Thirdly, some of the unethical trials are of a recent date, some were 
even being carried out in 2005 or later. Although it is sometimes 
argued that instances of unethical clinical trials are isolated and 
outdated, this is not always true. Note that some older cases have 
been included in the overview as well, mainly because the 
developments following these trials are still going on.  
And finally, the nature of ethical concerns appears to be rather 
diverse and relates to all paragraphs of the DoH summarized above.  
The lack of voluntary, informed participation and adequately 
informed consent are probably the most common problems. Cases of 
trials that did not undergo adequate ethical review or failed to 
report serious adverse events indicate flaws in the regulation of 
clinical trials. Tests with experimental drugs of which the safety for 
testing in humans had not yet been fully established may be among 
the most alarming examples. 
Examples of unethical trials 
Letrozole trials in India 
Letrozole trials in India Drugs:  letrozole  
Treatment Inducing ovulation  
Sponsors Sun Pharmaceuticals  
Period 2003  
Location  India  
Unethical aspects 
Letrozole, which belongs to the group of aromatase inhibitors, was 
tested by Sun Pharmaceuticals to induce ovulation. The drug has 
been approved globally for the treatment of breast cancer in post-
menopausal women, but it is not approved for any other use in any 
country. without their knowledge or consent to take part in clinical 
trials conducted at nine or more centres across.                                                                                                                         
Outcome 
A complaint on the letrozole case was filed in the Supreme Court by 
the Delhi-based NGO Social Jurist. Novartis, who was not involved 
with the study but markets letrozole under the brand name Femara, 
sent a clarification letter to all infertility experts in India to remind 
them of the approved indication india. 
Streptokinase trials in India 
Unethical aspects  
The companies had openly conducted illegal phase III clinical trials 
of new drugs on unaware patients and had conducted improper 
clinical trials without permission from the Genetic Engineering 
Approval Committee (GEAC). Eight patients died. Shanta Biotechnics 
denied the allegations.  
Violated norms 
The trial protocol was not reviewed by an ethical review committee. 
Subjects were not informed they were participating in a trial. 
Informed consent was not obtained. 
Risperidone trials in India 
Unethical aspects 
During a trial for the treatment of acute mania, psychiatric patients 
were taken off their existing medication and told that it was 
discontinued and no longer available. They subsequently received 
risperidone or a placebo. This was controversial because the 
patients receiving a placebo could suffer unnecessary harm by being 
taken off their medication. One patient explained that he signed a 
form because the doctor required it, but had no idea that he was 
participating in a clinical trial.  
Violated norms 
Not all subjects were informed they were participating in a trial.  
Informed consent was not properly obtained from all participants.  
Drugs:  risperidone (Risperdal)  
Treatment:  Treatment of acute mania  
Sponsors:  Johnson & Johnson  
Period:  Unclear, probably 2003  
Location:  Gujarat, India  
Drugs:  streptokinase (Streptokinnese / Streptase) and  
 insulin  
Treatme
nt:  
Clot-busting drug used in heart attacks, diabetes 
Sponsors
:  
Shanta Biotechnics (streptokinase), Biocon 
 (insulin)  
Period:  2003  
Location:  Hyderabad, India  
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The use of a placebo was controversial because it was unnecessarily 
dangerous.  It was not explained to all patients that the provided 
medical care was linked to a research.  
Outcome 
Johnson & Johnson denies the allegations and stated that consent 
had been obtained from every patient. It defended that placebo-
controlled trial expose less patients to a potentially ineffective 
treatment. However, this does not explain while patients have to 
discontinue a proven existing treatment 
Cilansetron trials in India 
Unethical aspects:  
Phase III trials involving cilansetron, a new molecule of Solvay 
Pharmaceuticals, were cleared by the Drugs Controller General of 
India (DCGI) even though only Phase II trials had been conducted 
abroad. At the time, trials of foreign drugs were permitted in India 
only at one step below the phase completed abroad.  
Violated norms:  
Before 2005, the Schedule Y of the Indian Drug and Cosmetic Act 
prohibited clinical trials in India of drugs developed outside the 
country before Phase II trials were completed abroad. Phase III trials 
of such drugs were only allowed if the drug had already been fully 
tested elsewhere. 
Zoniporide trials in India 
Drugs zoniporide  
Treatment  Perioperative cardiac events  
Sponsors Pfizer  
Period Unclear, probably around 2000  
Location India  
Unethical aspects:  
The Drugs Controller General of India (DCGI) approved Phase III 
trial of Pfizer's zoniporide while Phase II trials had not been 
completed in the USA and carcinogenic and reproductive studies on 
animals mandated by Indian law had not been completed.  
Violated norms 
Required animal experiments had not yet been completed.  Before 
2005, the Schedule Y of the Indian Drug and Cosmetic Act prohibited 
clinical trials in India of drugs developed outside the country before 
Phase II trials were completed abroad. Phase III trials of such drugs 
were only allowed if the drug had already been fully tested 
elsewhere.  
Cilostazol trials in India 
Unethical aspects:  
Drug trials were cleared by the Drugs Controller General of India 
(DCGI) based on incomplete, inadequate information on adverse 
effects. Common serious side-effects such as angina and myocardial 
infarction were not mentioned.  
NDGA trials in India 
Unethical aspects:  
The drug was tried on 26 cancer patients before its safety was 
established in animal tests. The patients were not informed that they 
were taking part in an experiment or that they were being denied an 
established treatment and two of them died. Subsequently, a 60-
year-old woman was again included for a trial in which the RCC 
provided five doses of the experimental drug. The woman's 
condition turned critical before the fifth dose but she survived.  
Violated norms  
 Required animal experiments had not yet been completed.  Subjects 
were not informed they were participating in a trial.  Informed 
consent was not obtained.  
Ragaglitazar trials in India 
Unethical aspects:  
Indian scientists questioned the ethics of the phase III clinical trials 
of the drug before it was fully tested on animals. The trials were 
conducted in 32 countries, inlcuding EU countries and the US, and 
involved 2,500 people. Novo Nordisk stated that prior approval had 
been obtained in each country. The trials were suspended by the 
company after it discovered a mouse (and several rats) treated with 
the drug had developed urinary bladder tumours. In India, 130 
people from eight centres participated in the trials. Half of them 
received the experimental drug.  
Violated norms 
It was disputed whether required animal experiments had been 
completed.  Under Indian Council of Medical Research (ICMR) 
regulations, the results of toxicity studies on drugs for chronic 
diseases had to be available before phase III clinical trials begin. In 
the EU and the US, this is not required.  
CONCLUSION 
The level of concern about the impact of the CTD on clinical research 
activities is intense and widespread overall stakeholder groups. 
Opinions and quantitative survey results draw a picture of increased 
bureaucracy and costs, reduction of important research without 
creating benefits for patients. However, concrete, comprehensive 
figures about the clinical trial activities are only available from 
competent authorities. Figures on the CTD’s impact on organisation, 
staffing, costs and processes of the different stakeholders are 
missing. 
Based  
These trials violated the the Indian Council of Medical Research’s 
Ethical guidelines for biomedical research on human subjects and 
the World Medical Association Declaration of Helsinki: Ethical 
principles for medical research involving human subjects. The trial 
designs do not seem to have violated regulations for the conduct of 
clinical research in India. The existing regulatory apparatus 
therefore permits unethical trials of no benefit to Indians. Clearly, 
trials are being conducted in India that could not be conducted in 
developed countries, taking advantage of people’s lack of access to 
affordable, good quality care.  
The benefits of research do not reach the community as drugs found 
effective following these trials may not be affordable to the 
community in which they were tested. Such practices are in violation 
of the Declaration of Helsinki as well as the general principles laid 
down in the Indian Council of Medical Research’s ethical guidelines 
for biomedical research. 
 
Drugs           cilansetron (Calmactin)  
Treatmt           Treatment  for diarrhoea from  
          Irritable Bowel Syndrome (IBS)  
Sponsor           Solvay Pharmaceuticals  
Period            Unclear, probably around 2000  
Locatio           India  
Drugs nordihydroguaiaretic acid (NDGA)  
Treatment Treatment for oral cancer  
Sponsors Johns Hopkins Hospital (US)  
Research organization  Regional Cancer treatment Center (RCC)  
Period 1999 – 2000  
Location Trivandrum, India  
Drugs ragaglitazar  
Treatment Diabetes treatment  
Sponsors Novo Nordisk  
Period 2002  
Location 32 countries, including India  
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The infrastructure for regulation, ethics review and monitoring is 
insufficient. The government’s priority seems to be ensuring that 
clinical research in India produces good quality data according to 
Good Clinical Practice standards. Ethical guidelines – including its 
own ethical guidelines – seem to be of secondary importance. The 
ethical concerns raised by these clinical trials; the weak regulatory 
apparatus to protect trial participants, government policy to 
encourage international clinical trials without taking active steps to 
put in place a system to protect participants from harm; people’s 
desperation for affordable health care – all this will only worsen the 
harm being done to trial participants in India.tum since the 
discussions that were convened by the IOM  
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